HER2 阳性乳腺癌转移患者最佳治疗方案的研究进展.

Trastuzumab, which was the first HER2-directed agent, has significantly improved outcomes for patients with HER2-positive metastatic breast cancer, however, drug resistance often happened. Other HER2-directed agents such as the pertuzumab,the tyrosine kinase receptor inhibitor lapatinib, and the immunoconjugate trastuzumab emtansine were developed to overcome resistance to trastuzumab and provide more options for patients. Recent data based on these HER2-directed agents has shown good clinical efficacy, but the optimal sequencing of treatments remains unclear. Meanwhile, with the emergence of new HER2-targeted agents, researches about the optimal sequencing become more and more meaningful. This review focused on the development of researches about the optimal sequencing and the condition of new HER2-directed agents nowadays. [ABSTRACT FROM AUTHOR]